CoChat

Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England

Open access
Perez-Guzman, Pablo N., Knock, Edward, Imai, Natsuko, Rawson, Thomas, Santoni, Cosmo Nazzareno, Alcada, Joana, Whittles, Lilith K., Thekke Kanapram, Divya, Sonabend, Raphael, Gaythorpe, Katy A. M., Hinsley, Wes, FitzJohn, Richard G., Volz, Erik, Verity, Robert, Ferguson, Neil M., Cori, Anne, Baguelin, Marc · 2023 · Nature Communications

Published version of a preprint

The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.

Abstract

As the SARS-CoV-2 pandemic progressed, distinct variants emerged and dominated in England. These variants, Wildtype, Alpha, Delta, and Omicron were characterized by variations in transmissibility and severity. We used a robust mathematical model and Bayesian inference framework to analyse epidemiological surveillance data from England. We quantified the impact of non-pharmaceutical interventions (NPIs), therapeutics, and vaccination on virus transmission and severity. Each successive variant had a higher intrinsic transmissibility. Omicron (BA.1) had the highest basic reproduction number at 8.4 (95% credible interval (CrI) 7.8-9.1). Varying levels of NPIs were crucial in controlling virus transmission until population immunity accumulated. Immune escape properties of Omicron decreased effective levels of immunity in the population by a third. Furthermore, in contrast to previous studies, we found Alpha had the highest basic infection fatality ratio (3.0%, 95% CrI 2.8-3.2), followed by Delta (2.1%, 95% CrI 1.9–2.4), Wildtype (1.2%, 95% CrI 1.1–1.2), and Omicron (0.7%, 95% CrI 0.6-0.8). Our findings highlight the importance of continued surveillance. Long-term strategies for monitoring and maintaining effective immunity against SARS-CoV-2 are critical to inform the role of NPIs to effectively manage future variants with potentially higher intrinsic transmissibility and severe outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-39661-5

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Population-level transmission of SARS-CoV-2 between March 2020 and February 2022 in England. a Infection positivity amongst individuals 15 years and older in the community through the national PCR testing programme (Pillar 2). b Infection prevalence (PCR) in representative samples of households from the REACT-1 study. Panels a and b show data in green (lines and point, with binomial 95% confidence intervals in error bars) and model trajectory in red (average and 95% credible interval (95% CrI)). Grey shading indicates periods of non-pharmaceutical interventions (NPIs) of interest for the analysis; see in f. For a complete list of modelled change points in contact rates see Supplement Table S11 and Figs. S28 and S29. c Model-inferred average frequency of daily infections by variant and type of infection (either primary or re-infection following any prior infection, “reinf”). d Intrinsic basic reproduction number (R0) estimates by variant (mean and 95% CrI). e Model trajectory of vaccine status of the national population (all ages as denominator), as informed by official data of daily doses administered (see sources in Table S1); transition between vaccination classes was modelled stochastically (Supplement section 3.2) to capture smooth changes in population-level immunity over time. f Model trajectories of the instantaneous reproduction number in the absence of the effect of immunity (Rt) or accounting for immunity (effective Rt). Legends and grey areas specify date and duration of official NPIs in England over the study period. g Inferred effective levels of immunity in the population (all ages as denominator). Lines correspond to the effective immunity against specific variants, with colour scheme as in c and d, whereas areas indicate overall effective immunity by type of immunity (vacc: vaccine-induced, inf: from prior infection, or hybrid). Note that the coloured areas corresponding to the different types of immunity cover different periods of variant dominance and should be interpreted in the context of the circulating variants (see Supplement section 4.8). During periods of variant replacement (e.g. Alpha to Delta) the effective immunity transitions from the levels associated with the variant being replaced to the level of the variant that becomes dominant.
Fig. 1 Population-level transmission of SARS-CoV-2 between March 2020 and February 2022 in England. a Infection positivity amongst individuals 15 years and older in the community through the national PCR testing programme (Pillar 2). b Infection prevalence (PCR) in representative samples of households from the REACT-1 study. Panels a and b show data in green (lines and point, with binomial 95% confidence intervals in error bars) and model trajectory in red (average and 95% credible interval (95% CrI)). Grey shading indicates periods of non-pharmaceutical interventions (NPIs) of interest for the analysis; see in f. For a complete list of modelled change points in contact rates see Supplement Table S11 and Figs. S28 and S29. c Model-inferred average frequency of daily infections by variant and type of infection (either primary or re-infection following any prior infection, “reinf”). d Intrinsic basic reproduction number (R0) estimates by variant (mean and 95% CrI). e Model trajectory of vaccine status of the national population (all ages as denominator), as informed by official data of daily doses administered (see sources in Table S1); transition between vaccination classes was modelled stochastically (Supplement section 3.2) to capture smooth changes in population-level immunity over time. f Model trajectories of the instantaneous reproduction number in the absence of the effect of immunity (Rt) or accounting for immunity (effective Rt). Legends and grey areas specify date and duration of official NPIs in England over the study period. g Inferred effective levels of immunity in the population (all ages as denominator). Lines correspond to the effective immunity against specific variants, with colour scheme as in c and d, whereas areas indicate overall effective immunity by type of immunity (vacc: vaccine-induced, inf: from prior infection, or hybrid). Note that the coloured areas corresponding to the different types of immunity cover different periods of variant dominance and should be interpreted in the context of the circulating variants (see Supplement section 4.8). During periods of variant replacement (e.g. Alpha to Delta) the effective immunity transitions from the levels associated with the variant being replaced to the level of the variant that becomes dominant.CC BY · PubMed Central
Fig. 2 Inferred severity of SARS-CoV-2 variants in England between March 2020 and February 2022. a–c Inferred basic and effective infection hospitalisation ratio (IHR, a), hospital fatality ratio (HFR, b) and infection fatality ratio (IFR, c). Boxplots to the left show the basic severity measure and trajectories to the right show severity measure over time (mean and 95% credible interval, 95% CrI) for each variant, with black showing the weighted average across co-circulating variants at any time. Basic severity is measured for each variant assuming healthcare characteristics of the early epidemic, to allow a like-for-like comparison. Effective severity trajectories account for changing vaccine- and infection-induced protection against severe disease, as well as underlying healthcare variations (see Table S8 for model time-varying severity parameters). d–f Age-specific (selected age groups) effective IHR (d), HFR (e) and IFR (f), assessed at the date of key milestones of the national vaccination programme, “rollout” refers to the start of the vaccination programme on 8th December 2020.
Fig. 2 Inferred severity of SARS-CoV-2 variants in England between March 2020 and February 2022. a–c Inferred basic and effective infection hospitalisation ratio (IHR, a), hospital fatality ratio (HFR, b) and infection fatality ratio (IFR, c). Boxplots to the left show the basic severity measure and trajectories to the right show severity measure over time (mean and 95% credible interval, 95% CrI) for each variant, with black showing the weighted average across co-circulating variants at any time. Basic severity is measured for each variant assuming healthcare characteristics of the early epidemic, to allow a like-for-like comparison. Effective severity trajectories account for changing vaccine- and infection-induced protection against severe disease, as well as underlying healthcare variations (see Table S8 for model time-varying severity parameters). d–f Age-specific (selected age groups) effective IHR (d), HFR (e) and IFR (f), assessed at the date of key milestones of the national vaccination programme, “rollout” refers to the start of the vaccination programme on 8th December 2020.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 47

Metadata

Authors
Perez-Guzman, P. N., Knock, E., Imai, N., Rawson, T., Santoni, C. N., Alcada, J., Whittles, L. K., Thekke Kanapram, D., Sonabend, R., Gaythorpe, K. A. M., Hinsley, W., FitzJohn, R. G., Volz, E., Verity, R., Ferguson, N. M., Cori, A., & Baguelin, M.
Affiliations
  • Imperial College London (GB)
  • National Institute for Health and Care Research (GB)
Corresponding author
Baguelin, Marc
Venue
Nature Communications
Published
2023-07-17
Volume
14
Issue
1
Pages
4279-4279
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4384499096
Cited by
42
References
40
Citations by year
2026: 6 · 2025: 12 · 2024: 21 · 2023: 3
FWCI
8.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
Funders
  • DH | National Institute for Health Research (NIHR200908)
  • Wellcome Trust (218669/Z/19/Z)
  • Department for International Development (DFID; 221350)
Topics
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
Keywords
SARS-CoV-2, SARS-CoV-2 variants, Omicron variant, Alpha variant, Delta variant, basic reproduction number, infection fatality rate, non-pharmaceutical interventions, vaccination, therapeutics, immune evasion, herd immunity, transmission dynamics, England
MeSH terms
COVID-19, SARS-CoV-2, Bayes Theorem, England, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. https://app.cochat.ai/papers/10.1038/s41467-023-39661-5
The paper
Perez-Guzman, P. N., Knock, E., Imai, N., Rawson, T., Santoni, C. N., Alcada, J., Whittles, L. K., Thekke Kanapram, D., Sonabend, R., Gaythorpe, K. A. M., Hinsley, W., FitzJohn, R. G., Volz, E., Verity, R., Ferguson, N. M., Cori, A., & Baguelin, M. (2023). Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. Nature Communications. https://doi.org/10.1038/s41467-023-39661-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.